* Slow † and easy ‡ inhalation enabled by active soft mist delivery 1 – 7
Bronchodilation is the cornerstone of COPD therapy 8 , 9
START WITH
SPIRIVA ®
RESPIMAT ® 9 , 10
Tiotropium , the only LAMA monotherapy indicated to reduce symptoms AND prevent
10 – 12
COPD exacerbations
UPGRADE TO
SPIOLTO ®
RESPIMAT ® 9 , 13
The only LAMA / LABA containing tiotropium , for proven benefits beyond
¶ 13 – 15
SPIRIVA Respimat alone
¶
Improves lung function , symptoms , and quality of life beyond SPIRIVA monotherapy .
†
Aerosol velocity 0.8 m / s consistent with the lower range of patient inspiratory flow rate . 3
‡
93 % of patients rated Respimat as “ very good ” or “ good ” for how easy it was to inhale from the device . 4
PBS Information : SPIOLTO Respimat . Authority required ( STREAMLINED ). Chronic obstructive pulmonary disease ( COPD ). Refer to PBS schedule for full authority information . SPIRIVA Respimat . Restricted benefit . Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease .
Please review Product Information before prescribing . Full Product Information is available at www . boehringer-ingelheim . com . au / PI . Further Information is available from Boehringer Ingelheim Pty Ltd .
SPIRIVA ® RESPIMAT ® ( tiotropium bromide ) solution for inhalation 2.5 microgram / actuation and SPIOLTO ® RESPIMAT ® 2.5 micrograms / 2.5 micrograms ( tiotropium ( as bromide monohydrate )/ olodaterol ( as hydrochloride )) solution for inhalation . INDICATIONS : SPIRIVA RESPIMAT : Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease ( COPD ). Prevention of COPD exacerbations . SPIOLTO RESPIMAT : Once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD . CONTRAINDICATIONS : SPIRIVA RESPIMAT and SPIOLTO RESPIMAT : Hypersensitivity to tiotropium bromide , olodaterol ( Spiolto only ), atropine or its derivatives , or to any of the excipients . PRECAUTIONS : SPIRIVA RESPIMAT and SPIOLTO RESPIMAT : Should not be used : more frequently than once daily ; for relief of acute symptoms , treatment of acute episodes of bronchospasm , immediate hypersensitivity reactions , paradoxical bronchospasm , narrow-angle glaucoma , prostatic hyperplasia , bladder neck obstruction , urinary retention , micturition difficulties , recent myocardial infarction (< 6 months for SPIRIVA , < 12 months for SPIOLTO ), unstable or life-threatening cardiac arrhythmia within past year , hospitalisation for heart failure within past year , moderate to severe renal impairment ( CrCL ≤ 50 mL / min ), pregnancy , lactation and children . Avoid solution or mist entering eyes . SPIRIVA RESPIMAT : Should not be used for : first-line treatment for asthma , dry mouth . SPIOLTO RESPIMAT : Should not be used : in treatment of asthma ( LABAs may increase the risk of asthma-related hospitalisations and death ); initiated in acutely deteriorating COPD , severe hepatic impairment , convulsive disorders , thyrotoxicosis , QT interval prolongation , unusual responsiveness to sympathomimetic amines ; increases in pulse rate , blood pressure and / or symptoms of clinically significant cardiovascular effect , paroxysmal tachycardia (> 100 beats per minute ), hypokalaemia , hyperglycaemia . INTERACTIONS : SPIRIVA RESPIMAT and SPIOLTO RESPIMAT : Co-administration with anticholinergic drugs . SPIOLTO RESPIMAT : Co-administration with adrenergic agents , xanthine derivatives , steroids , non-potassium sparing diuretics , beta-blockers , MAO inhibitors , tricyclic antidepressants , QTc interval prolonging drugs , LAMAs , LABAs . ADVERSE EFFECTS : SPIRIVA RESPIMAT : Common : Dry mouth , usually mild . SPIOLTO RESPIMAT : Very common : nasopharyngitis . Common : pneumonia , bronchitis , influenza , urinary tract infection , sinusitis , cough , dyspnoea , back pain , overdose , headache . Others , see full PI . DOSAGE : SPIRIVA RESPIMAT : For oral inhalation . 5 µ g tiotropium given as two puffs once daily , at the same time each day . SPIOLTO RESPIMAT : For oral inhalation . 5 µ g tiotropium and 5 µ g olodaterol given as two puffs once daily , at the same time each day . Do not exceed recommended dose . Cartridges to be used only with RESPIMAT inhaler . March 2020 .
Abbreviations : COPD : chronic obstructive pulmonary disease ; LABA : long-acting ß 2 agonist ; LAMA : long-acting muscarinic antagonist .
References : 1 . SPIRIVA Respimat Consumer Medicine Information , March 2020 . 2 . SPIOLTO Respimat Consumer Medicine Information , March 2020 . 3 . Wachtel H et al . Pulm Ther 2017 ; 3 ( 1 ): 19 – 30 . 4 . Hodder R , Price D . Int J COPD 2009 ; 4:381 – 90 . 5 . Schürmann W et al . Treat Respir Med 2005 ; 4:53 – 61 . 6 . Kardos P et al . Eur Respir J 2005 ; 26 ( Suppl 49 ): 338s . 7 . Dalby RN et al . Med Devices ( Auck ) 2011:4:145 – 55 . 8 . Global Initiative for Chronic Obstructive Lung Disease ( GOLD ). Global strategy for diagnosis , management and prevention of COPD . 2021 . 9 . Yang IA et al . COPD-X Concise Guide . Brisbane . Lung Foundation Australia . 2019 . 10 . SPIRIVA Respimat Approved Product Information , June 2020 . 11 . SPIRIVA Capsules Approved Product Information , June 2021 . 12 . Therapeutic Goods Administration Website . Available at : www . ebs . tga . gov . au ( accessed September 2021 ). 13 . SPIOLTO Respimat Approved Product Information , November 2020 . 14 . Buhl R et al . Eur Respir J 2015 ; 45 ( 4 ): 969 – 79 . 15 . Singh D et al . Respir Med 2015 ; 109 ( 10 ): 1312 – 9 .
SPIRIVA ® , SPIOLTO ® and RESPIMAT ® are registered trademarks of Boehringer Ingelheim . Boehringer Ingelheim Pty Ltd . ABN 52 000 452 308 . 78 Waterloo Road , North Ryde , NSW 2113 . PC-AU-102399 . BICO23686W . November 2021 .